Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.…
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Shattuck Labs (NASDAQ: STTK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 40 employees.
The shares were at 4.460 USD on 20 November 2026, up 127.6% over 52 weeks. Its 52-week range is 1.720 USD to 8.330 USD: the price is 46.5% below the high and 159.3% above the low.
Its market capitalisation is 454.22M USD.
Shattuck Labs reports return on equity of -59.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 193.86M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 15.40 USD is 245.3% above the current price. The next earnings report is expected on 11 March 2027.